Text Size

An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in mCRC

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Daiichi Sankyo Co., Ltd.
ClinicalTrials.gov Identifier:
NCT01039506
First received: December 23, 2009
Last updated: March 28, 2013
Last verified: March 2013
History of Changes
  Purpose

The purpose of this study is to examine the correlation between UGT1A1 genotypes and the efficacy of CPT-11 based regimens (FOLFIRI, CPT-11+S-1, CPT-11) for patients with metastatic colorectal cancer.


Condition Intervention
Metastatic Colorectal Cancer
 Drug: CPT-11 based regimens

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Prospective Observational Study of the Efficacy and Safety of CPT-11 Based Regimens for UGT1A1 Genotype Guided Patients With Metastatic Colorectal Cancer

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Daiichi Sankyo Co., Ltd.:

Primary Outcome Measures:
  • Progression free survival [ Time Frame: every two or three months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall survival, Time to treatment failure, response rate, disease control rate, safety [ Time Frame: adverse events will be collected during treatment ] [ Designated as safety issue: Yes ]

Biospecimen Retention:   Samples With DNA

white cells


Estimated Enrollment: 2000
Study Start Date: October 2009
Estimated Study Completion Date: March 2016
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
UGT1A1 genotpyed patients Drug: CPT-11 based regimens
FOLFIRI, CPT-11+S-1, CPT-11

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients with metastatic colorectal cancer treated with CPT-11 based regimens (FOLFIRI, CPT-11+S-1, CPT-11) in clinical practice in Japan

Criteria

Inclusion Criteria:

  • Metastatic colorectal cancer (adenocarcinoma)
  • UGT1A1 genotyped patients
  • Patients to receiving FOLFIRI, CPT-11+S-1 and CPT-11 alone therapy (with or without molecular targeted agents)

Exclusion Criteria:

  • Contraindication of CPT-11
  • ECOG PS 3-4
  • Patients to receiving CPT-11 as adjuvant chemotherapy
  • History of pelvic irradiation
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01039506

Locations
Japan
Department of Clinical Oncology, National Defense Medical College Hospital
Tokorozawa, Saitama, Japan, 359-8513
Sponsors and Collaborators
Daiichi Sankyo Co., Ltd.
Investigators
Principal Investigator: Wataru Ichikawa, MD. PhD. Department of Clinical Oncology, National Defense Medical College
  More Information

No publications provided

Responsible Party: Daiichi Sankyo Co., Ltd.
ClinicalTrials.gov Identifier: NCT01039506     History of Changes
Other Study ID Numbers: TOP009-061
Study First Received: December 23, 2009
Last Updated: March 28, 2013
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Daiichi Sankyo Co., Ltd.:
UGT1A1, irinotecan

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
 Irinotecan
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Radiation-Sensitizing Agents
Physiological Effects of Drugs
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 16, 2013